Bristol Myers Squibb has signed a deal worth up to 15.2 billion dollars with Jiangsu Hengrui Medicine, China’s largest pharmaceutical company by market capitalisation. The agreement covers 13 early-stage drug programmes across oncology, haematology, and immunology. None of the drugs have entered human clinical trials. The deal was announced on the same day that […] This story continues at The Next Web